[well365]

Inhibition of fatty acid metabolism - impact on myeloma?

by well365 on Sat Oct 05, 2013 12:23 pm

Hello all

Would someone please comment on this article:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046484

Essentially the article is about how the inhibition of fatty acid metabolism reduces human myeloma cells proliferation. I'm unclear how this works and if we know more. Its rather recent. Sounds promising.

Does this mean we need a diet high in "good" fatty acid? How do we slow down the metabolism of fatty acid?

Thanks for your input!

Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation
PLoS One. 2012;7(9):e46484
Tirado-Vélez JM, Joumady I, Sáez-Benito A, Cózar-Castellano I, Perdomo G.

Abstract: Multiple myeloma is a haematological malignancy characterized by the clonal proliferation of plasma cells. It has been proposed that targeting cancer cell metabolism would provide a new selective anticancer therapeutic strategy. In this work, we tested the hypothesis that inhibition of β-oxidation and de novo fatty acid synthesis would reduce cell proliferation in human myeloma cells. We evaluated the effect of etomoxir and orlistat on fatty acid metabolism, glucose metabolism, cell cycle distribution, proliferation, cell death and expression of G1/S phase regulatory proteins in myeloma cells. Etomoxir and orlistat inhibited β-oxidation and de novo fatty acid synthesis respectively in myeloma cells, without altering significantly glucose metabolism. These effects were associated with reduced cell viability and cell cycle arrest in G0/G1. Specifically, etomoxir and orlistat reduced by 40–70% myeloma cells proliferation. The combination of etomoxir and orlistat resulted in an additive inhibitory effect on cell proliferation. Orlistat induced apoptosis and sensitized RPMI-8226 cells to apoptosis induction by bortezomib, whereas apoptosis was not altered by etomoxir. Finally, the inhibitory effect of both drugs on cell proliferation was associated with reduced p21 protein levels and phosphorylation levels of retinoblastoma protein. In conclusion, inhibition of fatty acid metabolism represents a potential therapeutic approach to treat human multiple myeloma.